Original Articles Open access

IgG4-related disease: findings from a retrospective cohort in Colombia

Authors

Published
3 November 2025
Section
Original Articles
DOI
10.4081/reumatismo.2025.1887

Abstract

Objective. IgG4-related disease (IgG4-RD) is a recently described fibroinflammatory disorder. The most common presentations include salivary and lacrimal gland hypertrophy, orbitary disease, autoimmune pancreatitis, retroperitoneal fibrosis, and tubulointerstitial nephritis. Lymphoplasmacytic infiltration, fibrosis, IgG4+ cell hyperplasia, and elevated IgG4 serum levels are the primary pathophysiological findings related to the disease. We describe for the first time the epidemiology and clinical manifestations in our country.

Methods. A descriptive study of patients from a retrospective cohort based on clinical records of adults with IgG4-RD treated between 2014 and 2021 in a high-complexity national center.

Results. 23,381 patients from 12 centers nationwide until December 2021 provided demographic data. We limited the search through ICD-10 coding: M358, M359, and M368, other specified systemic involvement of connective tissue; L948, other specified localized connective tissue disorders; D472, monoclonal gammopathy; K861, other chronic pancreatitis; H051, H059, and H063, chronic inflammatory disease of orbit; and C488, malignant neoplasm of overlapping sites of retroperitoneum and peritoneum. Thirty-three patients were identified with IgG4-RD based on comprehensive diagnostic criteria. A definitive diagnosis was obtained in 48.48% of patients, a probable diagnosis in 27.7%, and a possible diagnosis in 24.24%. A total of 21 patients were female, with a male/female (M/F) ratio of 1/1.75. The median age at diagnosis was 53.87 years (interquartile range of 27.06), the minimum age of diagnosis was 11.53 years, and the maximum was 79.18 years. Regarding clinical presentation at diagnosis, ocular/orbitary involvement was present in 16 patients (48.48%), followed by head and neck in 10 patients (30.30%), and biliary tract/gastrointestinal in 9 (27.27%). A single-organ compromise was identified in 15 patients (45.45%), and 18 patients (54.55%) had two or more organs affected, with lymphatic and ocular/orbitary being the most commonly reported.

Conclusions. Epidemiologic and demographic data on IgG4-RD in our country are similar to those in the world medical literature. The higher frequency of the disease in males above 65 years and females under 65 years suggests distinct pathophysiologic factors related to sex and age. This work has a limitation of subreports or misreports, which physicians can make when registering ICD-10 codes in clinical records. Nonetheless, it is the legal record in Colombia and requires an analysis like the one made in this study.

Keywords

Ethics Approval

All procedures performed in this study were according to the ethical standards of the Research Ethics Committee of Artmedica IPS (Approval No. 2021001), followed by the 1964 Helsinki Declaration and its later amendments and national ethical standards (Resolution 8430 of 1993). The Artmedica's Research Ethics Committee reviewed and approved the study and the use of the medical records under the data privacy laws for clinical studies and scientific publications.

References

  1. Maritati F, Peyronel F, Vaglio A. IgG4-related disease: a clinical perspective. Rheumatology 2020; 59: iii123-31. DOI: https://doi.org/10.1093/rheumatology/kez667
  2. Research Committee to establish diagnostic criteria, of treatment for systemic IgG4-related sclerosing disease, Research Committee to establish a new clinical entity, IgG4-related multi-organ lymphoproliferative syndrome (IgG 4-MOLPS). Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Research Program of Intractable Disease provided by the Ministry of Health, Labor, and Welfare of Japan. Nihon Naika Gakkai Zasshi 2012; 101: 795-804. [Article in Japanese]. DOI: https://doi.org/10.2169/naika.101.795
  3. Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 2012; 22: 21-30. DOI: https://doi.org/10.1007/s10165-011-0571-z
  4. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012; 25: 1181-92. DOI: https://doi.org/10.1038/modpathol.2012.72
  5. Wang L, Zhang P, Zhang X, Lin W, Tang H, Li J, et al. Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: a prospective study of 403 patients. Rheumatology 2019; 58: 820-30. DOI: https://doi.org/10.1093/rheumatology/key397
  6. Zhang PP, Zhao JZ, Wang M, Feng RE, Liu XW, Lai XM, et al. The clinical characteristics of 346 patients with IgG4-related disease. Zhonghua Nei Ke Za Zhi 2017; 56: 644-9. [Article in Chinese].
  7. Inoue D, Yoshida K, Yoneda N, Ozaki K, Matsubara T, Nagai K, et al. IgG4-related disease: dataset of 235 consecutive patients. Medicine 2015; 94: e680. DOI: https://doi.org/10.1097/MD.0000000000000680
  8. Martín-Nares E, Baenas DF, Cuellar Gutiérrez MC, Hernández-Molina G, Ortiz AC, Neira O, et al. Clinical and serological features in Latin American IgG4-related disease patients differ according to sex, ethnicity, and clinical phenotype. J Clin Rheumatol 2022; 28: 285-92. DOI: https://doi.org/10.1097/RHU.0000000000001787
  9. Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M, Pillai S, Stone JH. IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol 2015; 67: 2466-75. DOI: https://doi.org/10.1002/art.39205
  10. Ebbo M, Daniel L, Pavic M, Sève P, Hamidou M, Andres E, et al. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine 2012; 91: 49-56. DOI: https://doi.org/10.1097/MD.0b013e3182433d77
  11. Campochiaro C, Ramirez GA, Bozzolo EP, Lanzillotta M, Berti A, Baldissera E, et al. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients. Scand J Rheumatol 2016; 45: 135-45. DOI: https://doi.org/10.3109/03009742.2015.1055796
  12. Fernández-Codina A, Martínez-Valle F, Pinilla B, López C, DeTorres I, Solans-Laqué R, et al. IgG4-related disease: results from a multicenter Spanish registry. Medicine 2015; 94: e1275. DOI: https://doi.org/10.1097/MD.0000000000001275
  13. Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 2015; 74: 14-8. DOI: https://doi.org/10.1136/annrheumdis-2013-204907
  14. Navarro EP, Suso JP, Chamorro M, Hormaza A, Echeverri A, Posso-Osorio I, et al. Espectro clínico de la enfermedad relacionada con IgG4 en Colombia. Rev Colomb Reumatol 2018; 25: 69-74. [Article in Spanish]. DOI: https://doi.org/10.1016/j.rcreu.2016.12.002
  15. Martín-Nares E, Hernandez-Molina G. What is the meaning of ANCA positivity in IgG4-related disease? Rheumatology 2021;60:3845-50. DOI: https://doi.org/10.1093/rheumatology/keab124

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2025 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.